GSK2330672 + GSK1614235

GSK2330672 + GSK1614235 appears to refer to a combination of two investigational small molecule drugs developed by GSK. GSK2330672, also known as linerixibat, is an orally bioavailable inhibitor of the ileal bile acid transporter (IBAT), primarily developed for the treatment of pruritus associated with primary biliary cholangitis (PBC). It functions by blocking the reabsorption of bile acids in the distal ileum, thereby reducing circulating bile acid levels and alleviating cholestatic pruritus[1][3][4][5][6]. There is no publicly available information on GSK1614235 as a distinct, clinically characterized molecule; its mechanism, indication, and role in combination with GSK2330672 remain unverified in public search results.